Forskning
Udskriv Udskriv
Switch language
Region Hovedstaden - en del af Københavns Universitetshospital
Udgivet

The effect of glucagon-like peptide-1 (GLP-1) receptor agonists on substance use disorder (SUD)-related behavioural effects of drugs and alcohol: A systematic review

Publikation: Bidrag til tidsskriftReviewForskningpeer review

  1. Post-oral fat-induced satiation is mediated by endogenous CCK and GLP-1 in a fat self-administration mouse model

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  2. Association between habitual sleep duration/quality and appetite markers in individuals with obesity

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  3. Novel GLP-1/GLP-2 co-agonists display marked effects on gut volume and improves glycemic control in mice

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  4. Decreased spontaneous activity in AMPK α2 muscle specific kinase dead mice is not caused by changes in brain dopamine metabolism

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  1. CalDAG-GEFI mediates striatal cholinergic modulation of dendritic excitability, synaptic plasticity and psychomotor behaviors

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  2. Alcohol use disorders and comorbidity

    Publikation: Bidrag til tidsskriftReviewForskningpeer review

  3. Ketogenic diet reduces alcohol withdrawal symptoms in humans and alcohol intake in rodents

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

Vis graf over relationer

Glucagon-like-peptide-1 (GLP-1)-receptor agonists have been proposed as putative treatment for substance use disorders (SUD). The objective of this systematic review is to characterize the effects of GLP-1-receptor agonists on SUD-related behavioural effects of drugs, nicotine, and alcohol. The review was performed according to Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA). A search was performed in PubMed and EMBASE on June 16, 2018. The inclusion criteria were primary studies investigating the use of GLP-1-receptor agonists on behavioural endpoints related to SUD. Seventeen studies were included, investigating the effect of the GLP-1-receptor agonists exendin-4, fluoro-exendin-4, liraglutide, AC3174 and GLP-1 (7-36) on SUD-related behavioural effects of ethanol, cocaine, amphetamine, and/or nicotine. All studies used rodents as subjects. Nine of the studies dealt with ethanol, six with cocaine, two with amphetamine, and two with nicotine. Most studies investigated acute treatment effects, finding a significant effect in all but one experiment. A few studies investigated more chronic effects on ethanol. All the studies reported sustained effects. Eleven studies tested more than one dose, finding a dose-related response in ten out of thirteen experiments. Six studies report a central effect through intra-cerebral administration or by using mice in which the central GLP-1-receptors had been inactivated. In conclusion, a solid body of evidence documents acute effects of GLP-1-receptor agonist treatment on behavioural effects of alcohol, nicotine, amphetamine and cocaine. Documentation of effect of more chronic GLP-1-receptor stimulation on these behaviours is limited.

OriginalsprogEngelsk
TidsskriftPhysiology & Behavior
Vol/bind206
Sider (fra-til)232-242
Antal sider11
ISSN0031-9384
DOI
StatusUdgivet - 1 jul. 2019

Bibliografisk note

Copyright © 2019. Published by Elsevier Inc.

ID: 59120512